22 Apr A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
Participant Eligibility
– Aged 18 to 75 years.
– Looking for treatment and are motivated to stop or cut down on drinking.
– Someone who drank alcohol regularly for the past 30 days at levels specified by the study (call the study phone number to see if you may be eligible)
Contact
Kai Orozco
(206) 743-5286
Additional Study Details
Full Study Title
A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)
Investigator(s)
Mark Duncan, MD
Mary Hatch, PhD
Accepts Healthy Volunteers?
No
Study Site(s)
University of Washington Medical Center – Montlake
1959 NE Pacific St.
Seattle, Washington 98195
